Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
24 participants
OBSERVATIONAL
2018-06-22
2023-01-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This sudy aims to evaluate the visual acuity during a 36 months period of time.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization
NCT02033018
Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy
NCT01950741
A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)
NCT04524910
Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
NCT02320474
Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)
NCT02860858
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AFLIBERCEPT
Patients will be treated following a real life protocol and according to the French recommendation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* High myopy defined by refractive error ≤ -6 D or History of high myopia among pseudophakic patient or patient treated with refractive surgery
* Patient with active CNVm
* • Patients naïve or Patients pretreated with previous history of laser photocoagulation or PDT or by other anti-VEGF treatments who did not receive injection since the last 3 month
* with OCT or angiography examination
Exclusion Criteria
* Treatment with PDT or laser administrated within 6 months prior to baseline in the study eye.
* History of vitrectomy in the study eye
* History of any other retinal disease
* VA less than 20/250
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu de Poitiers
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VIC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.